Xgeva (denosumab)

**Line(s) of Business:**
HMO; PPO; QUEST Integration
Akamai Advantage

**Original Effective Date:**
10/01/2015

**Current Effective Date:**
03/01/2018 TBD

**P O L I C Y**

A. **INDICATIONS**

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

**FDA-Approved Indications**

- Prevention of skeletal-related events in patients with bone metastases from solid tumors
  - Limitation of Use: Not indicated for the prevention of skeletal-related events in patients with multiple myeloma
- Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity
- Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy

B. **REQUIRED DOCUMENTATION**

The following information may be necessary to initiate the prior authorization review (where applicable):

- Bone metastases from a solid tumor:
  - Documentation of primary cancer (e.g., breast, prostate) from member’s chart notes
- Giant cell tumor of the bone
  - Documentation of clinical notes and active findings such as imaging studies (for continuation of therapy requests only)
- Hypercalcemia of malignancy:
  - Documentation of pre-treatment albumin-corrected serum calcium level (for new starts only)
  - Documentation of current albumin-corrected serum calcium level (for continuation of therapy requests only)

C. **CRITERIA FOR APPROVAL**

1. **Bone Metastases from a Solid Tumor**

Authorization of 24 months indefinite approval may be granted to members who are prescribed Xgeva for the prevention of skeletal-related events when the following criteria are met:
a. Member has bone metastases from a solid tumor.
b. Member will receive calcium and vitamin D as needed to treat or prevent hypocalcemia.
2. Giant Cell Tumor of Bone
   Authorization of 624 months may be granted to members who are prescribed Xgeva for giant cell tumor of bone when the following criteria are met:
   a. Member has unresectable disease or surgical resection is likely to result in severe morbidity.
   b. Member will receive calcium and vitamin D as needed to treat or prevent hypocalcemia.

3. Hypercalcemia of Malignancy
   Initial authorization of 2 months may be granted to members who are prescribed Xgeva for hypercalcemia of malignancy when the following criteria are met:
   a. Pre-treatment albumin-corrected serum calcium level is greater than 12.5 mg/dL
   b. The hypercalcemia is refractory to IV bisphosphonate therapy OR member has a contraindication to IV bisphosphonate therapy.

D. CONTINUATION OF THERAPY

1. No previous authorization/precertification:
   All members (including new members and members currently receiving treatment without prior authorization) must meet criteria for initial approval in section C. Members with bone metastases from solid tumors or giant cell tumor of bone requesting authorization for continuation of therapy must receive calcium and vitamin D as needed to treat or prevent hypocalcemia.

   Members with hypercalcemia of malignancy requesting authorization for continuation of therapy must demonstrate a response to Xgeva therapy defined as albumin-corrected serum calcium level of < 12.5 mg/dL.

   Bone Metastases from a Solid Tumor

   2. Reauthorization:
      a. Giant Cell Tumor of Bone
         Members who were previously approved for Xgeva by HMSA/CVS may request reauthorizations after their initial approval. Approval for an additional 6 months may be granted if the following information is supplied:
            i. A current oncology note documenting the patient’s response to treatment showing no progression of disease
            ii. Current imaging studies and other objective measures showing no progression of disease when compared with previous results
         Authorization of 6 months may be granted to New starts on therapy must meet all criteria in Section C.
         Members continuing with therapy must receive calcium and vitamin D as needed to treat or prevent hypocalcemia. Members who are prescribed Xgeva for continuation of therapy if Xgeva was previously authorized by HMSA/CVS and there is evidence of a lack of disease progression on therapy.

      b. Hypercalcemia of Malignancy
         Authorization of 24 months may be granted to members who are prescribed Xgeva for continuation of therapy if Xgeva was previously authorized by HMSA/CVS and
**Hypercalcemia of Malignancy**

New starts on therapy must meet all criteria in Section C. Members continuing with therapy must demonstrate a response to Xgeva therapy defined as albumin-corrected serum calcium level of < 12.5 mg/dL.

**E. DOSAGE AND ADMINISTRATION**

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

**F. ADMINISTRATIVE GUIDELINES**

Precertification is required. Please refer to the [HMSA medical policy web site](http://www.nccn.org) for the fax form.

**G. IMPORTANT REMINDER**

The purpose of this Medical Policy is to provide a guide to coverage. This Medical Policy is not intended to dictate to providers how to practice medicine. Nothing in this Medical Policy is intended to discourage or prohibit providing other medical advice or treatment deemed appropriate by the treating physician.

Benefit determinations are subject to applicable member contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control.

This Medical Policy has been developed through consideration of the medical necessity criteria under Hawaii’s Patients’ Bill of Rights and Responsibilities Act (Hawaii Revised Statutes §432E-1.4), generally accepted standards of medical practice and review of medical literature and government approval status. HMSA has determined that services not covered under this Medical Policy will not be medically necessary under Hawaii law in most cases. If a treating physician disagrees with HMSA’s determination as to medical necessity in a given case, the physician may request that CVS/caremark reconsider the application of the medical necessity criteria to the case at issue in light of any supporting documentation.

**H. REFERENCES**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/2017</td>
<td>Annual review</td>
</tr>
<tr>
<td>03/01/2018 TBD</td>
<td>Revision effective date</td>
</tr>
</tbody>
</table>